Table 9.6i
Immunosuppression Use for Antirejection Treatment from Transplant to One Year Following Transplantation, 1995 to 2004
Recipients with Liver Transplants

	Year of Transplant									
	1995	1996	1997	1998	1999	2000	2001	2002	2003	2004
Transplants	3,934	4,082	4,186	4,516	4,751	4,995	5,190	5,331	5,672	6,167
Tx with Antirejection Treatments	1,340	1,305	1,326	1,185	1,466	1,500	1,421	1,300	1,039	988
Antibodies										
Any in Category	21.9%	13.3%	12.1%	13.1%	12.5%	14.5%	16.7%	17.5%	18.0%	21.3%
ALG	0.9%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Atgam/NRATG/NRATS	1.4%	2.1%	1.4%	1.4%	0.7%	0.5%	0.5%	0.6%	0.8%	0.8%
OKT3	20.4%	11.9%	11.1%	9.7%	6.8%	6.3%	6.7%	6.0%	5.4%	5.8%
Thymoglobulin	0.0%	0.0%	0.0%	0.3%	1.4%	3.2%	5.1%	5.6%	7.0%	11.3%
Zenapax	0.0%	0.0%	0.2%	0.9%	1.7%	2.4%	1.6%	1.9%	1.4%	3.4%
Simulect	0.0%	0.0%	0.1%	1.2%	3.1%	3.1%	4.2%	4.0%	3.1%	0.7%
Campath	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.6%	2.0%	1.4%
Corticosteroids										
Any in Category	83.6%	83.8%	83.9%	87.3%	89.5%	90.7%	89.0%	90.2%	91.6%	88.6%
Steroids	83.6%	83.8%	83.9%	87.3%	89.5%	90.7%	89.0%	90.2%	91.6%	88.6%
Antimetabolites										
Any in Category	0.6%	0.2%	0.7%	0.3%	0.2%	0.1%	0.1%	0.0%	0.1%	0.0%
Cytoxan	0.6%	0.2%	0.7%	0.3%	0.2%	0.1%	0.1%	0.0%	0.1%	0.0%
Methotrexate	0.0%	0.1%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%

Source: OPTN/SRTR Data as of May 1, 2006.
Notes:
Individual drug percentages will not necessarily add up to the drug category percentages, as patients may be prescribed more than one drug within the same category.